Literature DB >> 23160988

Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels.

Eldo V Kuzhikandathil1, Samantha Cote, Soumava Santra, Aloke K Dutta.   

Abstract

This study aims to determine the effect of the novel D(3) dopamine receptor agonist, D-264, on activation of D(3) and D(2) dopamine receptor signal transduction pathways and cell proliferation. AtT-20 neuroendocrine cells stably expressing human D(2S), D(2L), and D(3) dopamine receptors were treated with D-264 and the coupling of the receptors to mitogen-activated protein kinase (MAPK) and G protein-coupled inward rectifier potassium (GIRK) channels was determined using Western blotting and whole-cell voltage clamp recording, respectively. D-264 potently activated MAPK signaling pathway coupled to D(2S), D(2L), and D(3) dopamine receptors. The activation of MAPK was more pronounced than the reference agonist quinpirole and was longer lasting. D-264 also activated GIRK channels coupled to D(2S), D(2L), and D(3) receptors. In addition, D-264 dose-dependently induced cell proliferation in AtT-D(2L) and AtT-D(3) cells. These results indicate that D-264 robustly activates GIRK channels and MAPK coupled to D(2) and D(3) dopamine receptors in AtT-20 cells. D-264 is also a potent inducer of cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23160988      PMCID: PMC3560311          DOI: 10.1007/s00210-012-0811-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  37 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome].

Authors:  B Giros; M P Martres; P Sokoloff; J C Schwartz
Journal:  C R Acad Sci III       Date:  1990

3.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.

Authors:  R K Sunahara; H C Guan; B F O'Dowd; P Seeman; L G Laurier; G Ng; S R George; J Torchia; H H Van Tol; H B Niznik
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

4.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

Review 5.  Molecular diversity of the dopamine receptors.

Authors:  O Civelli; J R Bunzow; D K Grandy
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

Review 6.  New insights into dopamine receptors in the central nervous system.

Authors:  P G Strange
Journal:  Neurochem Int       Date:  1993-03       Impact factor: 3.921

7.  Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.

Authors:  O Rascol; D J Brooks; E R Brunt; A D Korczyn; W H Poewe; F Stocchi
Journal:  Mov Disord       Date:  1998-01       Impact factor: 10.338

8.  D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes.

Authors:  P Werner; N Hussy; G Buell; K A Jones; R A North
Journal:  Mol Pharmacol       Date:  1996-04       Impact factor: 4.436

9.  The neuropathologic basis of different clinical subgroups of Parkinson's disease.

Authors:  W Paulus; K Jellinger
Journal:  J Neuropathol Exp Neurol       Date:  1991-11       Impact factor: 3.685

10.  Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.

Authors:  Z Xia; M Dickens; J Raingeaud; R J Davis; M E Greenberg
Journal:  Science       Date:  1995-11-24       Impact factor: 47.728

View more
  1 in total

Review 1.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.